[ad_1]
The Swedish Medicines Agency is now collaborating with German authorities to analyze raw data from remedy studies to make a joint decision that will apply across the EU.
“We are seeing if the benefits outweigh the risks,” Charlotta Bergquist, director of the infection group at the Swedish Medicines Agency, told TV4.
According to her, a decision will probably come in a few days.
“It goes as fast as possible. You work on the weekend, there is nothing to wait for Monday, “she says.
The message comes after the US FDA. USA He would grant an emergency approval to redeploy on Friday, something Di previously reported. The antecedent to the approval was a US study that was presented Wednesday and showed that the drug reached its main goals.
Patients who were hospitalized and treated with remdesivir recovered on average after 11 days, while the group that received the so-called placebo recovered on average 15 days.
The news about the crown jump remdesivir has had a significant impact on the markets. When the positive study was presented on Wednesday, a clear increase was noted in the world’s stock exchanges.
Di analyst Johan Wendel has written that remdesivir does not appear to be a miracle cure, but that it may be a first step. The drug is an antiviral drug, which means that the goal is to prevent the virus from multiplying.
